1) Klatt, E.C., 2017. Pathology of HIV/AIDS. The Mercer University of Medicine Savannah, pp.6-50.
2) Arora, S.K. and Mehta, G., 2018. HIV-AIDS: An unconquered immunewar. Infectious Diseases and Your Health, pp.337-348.
3) De Cock, K.M., Jaffe, H.W. and Curran, J.W., 2012. The evolving epidemiology of HIV/AIDS. Aids, 26(10), pp.1205-1213.
4) Peruski, A.H., Wu, B., Linley, L., Delaney,
K.P., DiNenno, E.A. and Johnson, A.S., 2021. Time from HIV infection to diagnosis in the US, 2014–2018. American journal of preventive medicine, 61(5), pp.636-643.
5) Kervevan, J. and Chakrabarti, L.A., 2021. Role of CD4+ T cells in the control of viral infections: recent advances and open questions. International Journal of Molecular Sciences, 22(2), p.523.
6) Tahir, N.B., Shah, M.M. and Uddin, Q.T., 2015. Assessment of different modes of transmission of HIV in Patients with HIV/AIDS. Gomal Journal of Medical Sciences, 13(3).
7) Simon, V., Ho, D.D. and Karim, Q.A., 2006. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. The Lancet, 368(9534), pp. 489-504.
8) Nambiar, P. and Short, W.R., 2019. Mechanisms of HIV Transmission Fundamentals of HIV Medicine 2019, p.20.
9) Pena-Cruz, V., Agosto, L.M., Akiyama, H., Olson, A., Moreau, Y., Larrieux, J.R., Henderson, A., Gummuluru, S. and Sagar, M., 2018. HIV-1 replicates and persists in vaginal epithelial dendritic cells. The Journal of clinical investigation, 128(8), pp.3439- 3444.
10) Chilaka, V.N. and Konje, J.C., 2021. HIV in pregnancy–An update. European Journal of Obstetrics & Gynecology and Reproductive Biology, 256, pp.484-491.
11) Bailey, H., Zash, R., Rasi, V. and Thorne, C., 2018. HIV treatment in pregnancy. The lancet HIV, 5(8), pp.e457-e467.
12) Ikumi, N.M., Matjila, M., Gray, C.M., Anumba, D. and Pillay, K., 2021. Placental pathology in women with HIV. Placenta, 115, pp.27-36.
13) Shiadeh, M.N., Esfandyari, S., Ashrafmansouri, M., Mirzapour, A., Taghipour, A., Spotin, A., Arefkhah, N., Gamble, R., Safa, A. and Rostami, A., 2020. The prevalence of latent and acute toxoplasmosis in HIV-infected pregnant women: A systematic review and meta- analysis. Microbial Pathogenesis, 149, p.104549.
14) Elijah, O.B., Umukoro, E.K., Moke, E.G., Igben, V.J.O., Arighwrode, O., Onakpoya, E.E., Dennis-Eboh, U. and Ekuerhare, B.E., 2024. Challenges of antimicrobial resistance in Sub-Saharan Africa: The past, present, and future perspectives. Orapuh Journal, 5(2), pp.e1120-e1120.
15) Zhang, F., Liu, L., Sun, M., Sun, J. and Lu, H., 2017. An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. PLoS One, 12(2), p.e0165110.
16) Watera, C., Ssemwanga, D., Namayanja, G., Asio, J., Lutalo, T., Namale, A., Sanyu, G., Ssewanyana, I., Gonzalez-Salazar, J.F., Nazziwa, J. and Nanyonjo, M., 2021. HIV drug resistance among adults initiating antiretroviral therapy in Uganda. Journal of Antimicrobial Chemotherapy, 76(9), pp.2407-2414.
17) Musoke, P., Namukwaya, Z. and Mosha, L.B., 2018. Prevention and treatment of pediatric HIV infection. Current Tropical Medicine Reports, 5, pp.24-30.
18) Thorne, C. and Newell, M.L., 2003. Mother- to-child transmission of HIV infection and its prevention. Current HIV research, 1(4), pp.447-462.
19) UNAIDS 2023 fact sheet https://www. unaids.org/en/resources/fact-sheet Accessed December 2023
20) Harris, K. and Yudin, M.H., 2020. HIV infection in pregnant women: a 2020 update. Prenatal Diagnosis, 40(13), pp. 1715- 1721.
21) Nigerian National Agency for the control of AIDS (NACA) 2023 statistics https://www.naca.gov.ng/wp-content/ uploads/2022/03/National-HIV-and-AIDS- Strategic-Framework-2021-2023- Final.pdf(Accessed in December 2023).
22) Nigerian National Agency for the control of AIDS (NACA) 2016 statistics https://naca.gov.ng/wp-content/uploads/2016/11/NACA-Annual-Report-20141_ 0.pdf (Accessed in December 2023)
23) Luppi, P., 2003. How immune mechanisms are affected by pregnancy. Vaccine, 21(24), pp. 3352-3357.
24) Dahl, V., Josefsson, L. and Palmer, S., 2010. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral research, 85(1), pp.286-294.
25) Tang, Y., Woodward, B.O., Pastor, L., George, A.M., Petrechko, O., Nouvet, F.J., Haas, D.W., Jiang, G. and Hildreth, J.E., 2020. Endogenous retroviral envelope syncytin induces HIV-1 spreading and establishes HIV reservoirs in placenta. Cell reports, 30(13), pp.4528-4539.
26) Al-Husaini, A.M., 2009. Role of placenta in the vertical transmission of human immunodeficiency virus. Journal of Perinatology, 29(5), pp.331-336.
27) Schwartz, D.A., Sungkarat, S., Shaffer, N., Laosakkitiboran, J., Supapol, W., Charoenpanich, P., Chuangsuwanich, T. and Mastro, T.D., 2000. Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand. The Journal of infectious diseases, 182(6), pp.1652-1657.
28) Chandrasekar, V., Singh, A.V., Maharjan, R.S., Dakua, S.P., Balakrishnan, S., Dash, S., Laux, P., Luch, A., Singh, S. and Pradhan, M., 2022. Perspectives on the Technological Aspects and Biomedical Applications of Virus‐Like Particles/Nanoparticles in Reproductive Biology: Insights on the Medicinal and Toxicological Outlook. Advanced NanoBiomed Research, 2(8), p.2200010.
29) Altfeld, M. and Bunders, M.J., 2016, November. Impact of HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health. In Seminars in immunopathology (Vol. 38, pp. 727-738). Springer Berlin Heidelberg.
30) Connor, E.M., Sperling, R.S., Gelber, R., Kiselev, P., Scott, G., O'sullivan, M.J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R.L. and Jimenez, E., 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine, 331(18), pp.1173-1180.
31) Guay, L.A., Musoke, P., Fleming, T., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Ducar, C., Deseyve, M. and Emel, L., 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to- child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. The Lancet, 354(9181), pp.795-802.
32) Paintsil, E. and Andiman, W.A., 2009. Update on successes and challenges regarding mother-to-child transmission of HIV. Current opinion in pediatrics, 21(1), p.94.
33) Chi, B.H., Adler, M.R., Bolu, O., Mbori- Ngacha, D., Ekouevi, D.K., Gieselman, A., Chipato, T., Luo, C., Phelps, B.R., McClure, C. and Mofenson, L.M., 2012. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President’s Emergency Plan for AIDS Relief. Journal of acquired immune deficiency syndromes (1999), 60(Suppl 3), p.S78
34) Newell, M.L., 2006. Current issues in the prevention of mother-to-child transmission of HIV-1 infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(1), pp.1-5.
35) Biggar, R.J., Goedert, J.J., Miotti, P.G., Taha, T.E., Mtimavalye, L., Justesen, A., Chiphangwi, J.D., Broadhead, R., Yellin, F., Liomba, G. and Miley, W., 1996. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. The Lancet, 347(9016), pp.1647-1650.
36) Taha, T.E., Kumwenda, N.I., Gibbons, A., Broadhead, R.L., Fiscus, S., Lema, V., Liomba, G., Nkhoma, C., Miotti, P.G. and Hoover, D.R., 2003. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. The Lancet, 362(9391), pp.1171-1177.
37) Lallemant, M., Jourdain, G., Le Coeur, S., Mary, J.Y., Ngo-Giang-Huong, N., Koetsawang, S., Kanshana, S., McIntosh, K. and Thaineua, V., 2004. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. New England Journal of Medicine, 351(3), pp.217-228.
38) United Nations. Declaration of commitment on HIV/AIDS. United Nations General Assembly Special Session on HIV/AIDS; 25– 27 Jun 2001; Geneva.
39) WHO, UNFPA, IPPF. Sexual and reproductive health & HIV/AIDS: a framework for priority linkages Geneva 2005. Available on https://www.who.int/reproductivehealth/publi cations/linkages/HIV_05_5/en/index.html. Accessed 20 June 2024
40) World Health Organization. Global guidance on criteria and processes for validation: Elimination of mother-to-child transmission of HIV and Syphilis, Second edition Geneva, Switzerland WHO; 2017. Available on https://apps.who.int/iris/bitstream/handle/106 65/259517/9789241513272-eng.pdf?sequence=1. Accessed 20 June 2024.
41) World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants Recommendations for a public health approach 2010 version Geneva, Switzerland: WHO; 2010. Available on https://apps.who.int/iris/bitstream/handle/106 65/75236/9789241599818_eng.pdf?sequence=1. Accessed 20 June 2024
42) Fowler, Mary Glenn, Hoosen Coovadia, Casey M. Herron, Yvonne Maldonado, Tsungai Chipato, Dhayendre Moodley, Philippa Musoke et al. "Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo- controlled trial." JAIDS Journal of Acquired Immune Deficiency Syndromes 65, no. 3 (2014): 366-374.
43) World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition Geneva, Switzerland WHO; 2016 [Available from: https://www.who.int/hiv/pub/arv/arv- 2016/en/. Accessed 20 June 2024.
44) Muyunda, B., Musonda, P., Mee, P., Todd, J. and Michelo, C., 2020. Effectiveness of lifelong ART (Option B+) in the prevention of mother-to-child transmission of HIV programme in Zambia: observations based on routinely collected health data. Frontiers in public health, 7, p.470826.
45) Astawesegn, F.H., Stulz, V., Conroy, E. and Mannan, H., 2022. Trends and effects of antiretroviral therapy coverage during pregnancy on mother-to-child transmission of HIV in Sub-Saharan Africa. Evidence from panel data analysis. BMC Infectious Diseases, 22(1), p.134.
46) Maingi, M., Stark, A.H. and Iron‐Segev, S., 2022. The impact of Option B+ on mother‐to‐child transmission of HIV in Africa: A systematic review. Tropical Medicine & International Health, 27(6), pp.553-563.
47) Anigilaje, E.A., Ageda, B.R. and Nweke, N.O., 2016. Barriers to uptake of prevention of mother-to-child transmission of HIV services among mothers of vertically infected HIV- seropositive infants in Makurdi, Nigeria. Patient preference and adherence, pp.57-72.
48) Fassinou, L.C., SongwaNkeunang, D., Delvaux, T., Nagot, N. and Kirakoya- Samadoulougou, F., 2024. Adherence to option B+ antiretroviral therapy and associated factors in pregnant and breastfeeding women in Sub-Saharan Africa: a systematic review and meta- analysis. BMC public health, 24(1), p.94.
49) World Health Organization (WHO). Validation of eliminating of mother-to- child transmission of HIV, syphilis and hepatitis B. 2023. Available on:https://www.who.int/initiatives/triple- elimination-initiative-of-mother-to-child- transmission-of-hiv-syphilis-and-hepatitis- b/validationAccessed 20 June 2024.
50) Quinn, T.C., 1996. Global burden of the HIV pandemic. The lancet, 348(9020), pp.99-106.
51) Liu, Z., Chen, Z., Cui, F., Ding, Y., Gao, Y., Han, G., Jia, J., Li, J., Li, Z., Liu, Y. and Mao, Q., 2022. Management algorithm for prevention of mother-to- child transmission of hepatitis B virus (2022). Journal of Clinical and Translational Hepatology, 10(5), p.1004.
52) World Health Organization, 2021. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus.
